Table 1 Patient/tumor characteristics and treatment.
Patient | Age | Subtype | MFI (y) | Metastatic sites (no) | PFS (mos) | Treatment | Treatment classification |
|---|---|---|---|---|---|---|---|
Pat 1 | 44 | ER +/HER2− | 0 | ≥3 | 5.5 | FEC | ChT |
Pat 2 | 72 | ER +/HER2− | 6.2 | <3 | 2.8 | TAM | ET |
Pat 3 | 71 | ER +/HER2− | 19.1 | <3 | 33.6 | AI | ET |
Pat 4 | 58 | ER +/HER2− | 0 | <3 | 22.3 | AI | ET |
Pat 5 | 45 | ER +/HER2− | 0 | <3 | 29.9 | TAM | ET |
Pat 6 | 63 | ER +/HER2− | 4.5 | ≥3 | 20.9 | FEC | ChT |
Pat 7 | 53 | ER +/HER2− | 3.8 | <3 | 33.9 | AI | ET |
Pat 8 | 77 | TNBC | 1.0 | ≥3 | 16.0 | CAPE + RT | ChT + RT |
Pat 9 | 56 | ER +/HER2+ | 4.8 | <3 | >56.7 | CAPE + trastuzumab + RT | ChT + RT |
Pat 10 | 50 | ER +/HER2− | 5.1 | ≥3 | 8.5 | docetaxel | ChT |
